A drug for type two diabetes is still being prescribed in the UK despite an official panel recommending it be withdrawn.

Avandia, which is marketed by GlaxoSmithKline has been linked to a raised risk of heart attacks and heart failure and is under a Europe-wide review.

An expert panel of the UK Medicines and Healthcare products Regulatory Agency (MHRA) said that prescriptions for the drug should be suspended, but despite this warning the medication is still available on the NHS.

GSK has strongly refuted the claims, saying the company has conducted relevant tests, the results of which were given to regulatory authorities worldwide and have shown the drug to be safe if monitored properly.